"Janus Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is predominantly expressed in hematopoietic cells. It is involved in signaling from a broad variety of CYTOKINE RECEPTORS including ones that utilize the INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT.
| Descriptor ID |
D053616
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.300 D12.776.476.393.300
|
| Concept/Terms |
Janus Kinase 3- Janus Kinase 3
- Kinase 3, Janus
- JAK-3 Protein Tyrosine Kinase
- JAK 3 Protein Tyrosine Kinase
- JAK3 Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 3".
This graph shows the total number of publications written about "Janus Kinase 3" by people in this website by year, and whether "Janus Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 1 | 1 |
| 1996 | 0 | 3 | 3 |
| 1997 | 0 | 2 | 2 |
| 1998 | 0 | 1 | 1 |
| 1999 | 0 | 2 | 2 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 3 | 3 |
| 2004 | 0 | 1 | 1 |
| 2005 | 0 | 2 | 2 |
| 2006 | 0 | 5 | 5 |
| 2009 | 2 | 0 | 2 |
| 2010 | 1 | 0 | 1 |
| 2011 | 1 | 0 | 1 |
| 2014 | 0 | 1 | 1 |
| 2015 | 1 | 0 | 1 |
| 2016 | 0 | 1 | 1 |
| 2023 | 1 | 1 | 2 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 3" by people in Profiles.
-
New JAK3-INSL3 Fusion Transcript-An Oncogenic Event in Cutaneous T-Cell Lymphoma. Cells. 2023 09 29; 12(19).
-
T-Cell Prolymphocytic Leukemia With t(X;14)(q28;q11.2): A Clinicopathologic Study of 15 Cases. Am J Clin Pathol. 2023 04 04; 159(4):325-336.
-
B-cell differentiation and IL-21 response in IL2RG/JAK3 SCID patients after hematopoietic stem cell transplantation. Blood. 2018 06 28; 131(26):2967-2977.
-
LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. J Clin Invest. 2016 Apr 01; 126(4):1267-81.
-
JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis. J Am Soc Nephrol. 2015 Dec; 26(12):3060-71.
-
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014 Aug 28; 124(9):1460-72.
-
Effects of topical Janus kinase inhibition on ocular surface inflammation and immunity. Cornea. 2014 Feb; 33(2):177-83.
-
Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011 Aug; 25(8):1365-8.
-
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. 2011 Oct; 29(5):818-26.
-
IL-21 contributes to JAK3/STAT3 activation and promotes cell growth in ALK-positive anaplastic large cell lymphoma. Am J Pathol. 2009 Aug; 175(2):825-34.